Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
47
PRTC Quote, Financials, Valuation and Earnings
Last price:
$18.47
Seasonality move
:
-2.57%
Day range:
$18.50 - $18.74
52-week range:
$13.30 - $25.00
Dividend yield:
0%
P/E ratio:
8.20x
P/S ratio:
309.63x
P/B ratio:
1.08x
Volume:
1.5K
Avg. volume:
4.4K
1-year change:
-20.26%
Market cap:
$446.9M
Revenue:
$4.3M
EPS (TTM):
-$3.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
-- | -- | -- | -- | $53.25 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
|
VOR
Vor Biopharma
|
-- | -$0.59 | -- | -46.95% | $1.18 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
$18.60 | $53.25 | $446.9M | 8.20x | $0.00 | 0% | 309.63x |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.64 | -- | $26.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.43 | $1.00 | $1M | -- | $0.00 | 0% | 0.46x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
|
VOR
Vor Biopharma
|
$2.12 | $1.18 | $264.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
-- | 0.576 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
|
VOR
Vor Biopharma
|
-- | 17.849 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRTC
PureTech Health PLC
|
-- | -- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
|
VOR
Vor Biopharma
|
-- | -$33.3M | -- | -- | -- | -$31.3M |
PureTech Health PLC vs. Competitors
-
Which has Higher Returns PRTC or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to PureTech Health PLC's net margin of -49.65%. PureTech Health PLC's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About PRTC or NBY?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 186.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that PureTech Health PLC has higher upside potential than NovaBay Pharmaceuticals, analysts believe PureTech Health PLC is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is PRTC or NBY More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock PRTC or NBY?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or NBY?
PureTech Health PLC quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. PureTech Health PLC's net income of -- is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, PureTech Health PLC's price-to-earnings ratio is 8.20x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 309.63x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC309.63x 8.20x -- -- NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns PRTC or NNVC?
Nanoviricides has a net margin of -- compared to PureTech Health PLC's net margin of --. PureTech Health PLC's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About PRTC or NNVC?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 186.29%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 296.34%. Given that Nanoviricides has higher upside potential than PureTech Health PLC, analysts believe Nanoviricides is more attractive than PureTech Health PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 NNVCNanoviricides0 0 0 -
Is PRTC or NNVC More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock PRTC or NNVC?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or NNVC?
PureTech Health PLC quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. PureTech Health PLC's net income of -- is lower than Nanoviricides's net income of -$2.2M. Notably, PureTech Health PLC's price-to-earnings ratio is 8.20x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 309.63x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC309.63x 8.20x -- -- NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns PRTC or OGEN?
Oragenics has a net margin of -- compared to PureTech Health PLC's net margin of --. PureTech Health PLC's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About PRTC or OGEN?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 186.29%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than PureTech Health PLC, analysts believe Oragenics is more attractive than PureTech Health PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 OGENOragenics0 1 0 -
Is PRTC or OGEN More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock PRTC or OGEN?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or OGEN?
PureTech Health PLC quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. PureTech Health PLC's net income of -- is lower than Oragenics's net income of -$2.2M. Notably, PureTech Health PLC's price-to-earnings ratio is 8.20x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 309.63x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC309.63x 8.20x -- -- OGENOragenics0.46x -- -- -$2.2M
-
Which has Higher Returns PRTC or TOVX?
Theriva Biologics has a net margin of -- compared to PureTech Health PLC's net margin of --. PureTech Health PLC's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About PRTC or TOVX?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 186.29%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than PureTech Health PLC, analysts believe Theriva Biologics is more attractive than PureTech Health PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 TOVXTheriva Biologics1 1 0 -
Is PRTC or TOVX More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock PRTC or TOVX?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or TOVX?
PureTech Health PLC quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. PureTech Health PLC's net income of -- is lower than Theriva Biologics's net income of -$4.3M. Notably, PureTech Health PLC's price-to-earnings ratio is 8.20x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 309.63x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC309.63x 8.20x -- -- TOVXTheriva Biologics0.33x -- -- -$4.3M
-
Which has Higher Returns PRTC or VOR?
Vor Biopharma has a net margin of -- compared to PureTech Health PLC's net margin of --. PureTech Health PLC's return on equity of -- beat Vor Biopharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTCPureTech Health PLC-- -- -- VORVor Biopharma-- -$0.26 -- -
What do Analysts Say About PRTC or VOR?
PureTech Health PLC has a consensus price target of $53.25, signalling upside risk potential of 186.29%. On the other hand Vor Biopharma has an analysts' consensus of $1.18 which suggests that it could fall by -44.58%. Given that PureTech Health PLC has higher upside potential than Vor Biopharma, analysts believe PureTech Health PLC is more attractive than Vor Biopharma.
Company Buy Ratings Hold Ratings Sell Ratings PRTCPureTech Health PLC2 0 0 VORVor Biopharma0 4 0 -
Is PRTC or VOR More Risky?
PureTech Health PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vor Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRTC or VOR?
PureTech Health PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PureTech Health PLC pays -- of its earnings as a dividend. Vor Biopharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTC or VOR?
PureTech Health PLC quarterly revenues are --, which are smaller than Vor Biopharma quarterly revenues of --. PureTech Health PLC's net income of -- is lower than Vor Biopharma's net income of -$32.5M. Notably, PureTech Health PLC's price-to-earnings ratio is 8.20x while Vor Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PureTech Health PLC is 309.63x versus -- for Vor Biopharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTCPureTech Health PLC309.63x 8.20x -- -- VORVor Biopharma-- -- -- -$32.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
72
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
